Research
Hormonal
Genetic disruption of core clock genes (e.g., Clock, Bmal1, Per) in mice leads to obesity, hyperphagia, and metabolic disorders, demonstrating a direct genetic link between circadian regulation and energy homeostasis.
Understand that your genetics play a role in how your body handles time and food. If you have a family history of metabolic issues, strict adherence to circadian hygiene (regular sleep/eating times) may be even more critical for you.
StrongSupportsHIGH confidence
Clock mutant mice are obese and hyperphagic... Global Bmal1 knockout mice are arrhythmic and display increased adiposity at early ages... mice with mutations in the Period genes display increased adiposity.
Why this rating
Based on well-established genetic animal models with clear phenotypic outcomes.
Source
Circadian rhythms, sleep, and metabolism
Wenyu Huang et al. · Journal of Clinical Investigation · 2011
DOI 10.1172/jci46043
narrative_reviewCited 713×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Feeding during the biological rest phase (daytime for mice, nighttime for humans) disrupts circadian alignment and promotes obesity and metabolic disorders, whereas aligning food intake with the active phase restores metabolic rhythms and prevents weight gain.Good
- Circadian disruption, such as that caused by shift work or sleep restriction, leads to insulin resistance, hypoleptinemia, and increased risk of obesity and type 2 diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →